{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:46Z","timestamp":1791216826215,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyze the clinical characteristics and influencing factors of hepatotoxicity in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death protein\u20101 (PD\u20101) inhibitors, and to provide a theoretical basis for the treatment of immune\u2010related hepatotoxicity in patients with advanced HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of clinical data of patients with advanced HCC from February 2021 to February 2023, in order to summarize and statistically analyze the influencing factors of immune\u2010related liver adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 135 patients met the inclusion criteria, among whom 46 patients experienced varying degrees of immune\u2010related liver adverse reactions, with an incidence rate of 34.1% (46\/135). The time range of immune\u2010related liver adverse reactions was 3\u201326\u2009weeks, with a median time of 4\u2009weeks. The age range of immune\u2010related liver adverse reactions was 34\u201373\u2009years, with a median age of 62\u2009years. Statistical analysis of the influencing factors and liver adverse reactions showed that age, total bilirubin level, and Child\u2013Pugh (C\u2013P) grading were influencing factors for the occurrence of liver adverse reactions (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05), and among these three influencing factors, the proportion of males with \u22652 influencing factors was higher than that of females; liver function C\u2013P B was an independent influencing factor for liver adverse reactions (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For male patients over 60\u2009years old, with bilirubin levels \u226551\u2009\u03bcmol\/L and liver function C\u2013P B, close observation of the occurrence of immune\u2010related adverse reactions during treatment is recommended.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1918","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T09:45:14Z","timestamp":1702287914000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-5704","authenticated-orcid":false,"given":"Rui","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery Hainan Cancer Hospital  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery Hainan Cancer Hospital  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Chengmei Hospital  Haikou Hainan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihu","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology Chengmei Hospital  Haikou Hainan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery Hainan Cancer Hospital  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zepeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery Hainan Cancer Hospital  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery Hainan Cancer Hospital  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102020\u20100669"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt\u20102021\u20100026"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010022\u201003349\u20104"},{"issue":"11","key":"e_1_2_10_5_1","first-page":"6","article-title":"Chinese expert consensus on the construction of a multidisciplinary diagnosis and treatment collaborative group on toxicity related to Immunocheckpoint inhibitors","volume":"29","author":"Chinese Clinical Oncology Society Immunotherapy Expert Committee, Chinese Clinical Oncology Society Antitumor Drug Safety Management Expert Committee","year":"2022","journal-title":"Chinese J Cancer Biother"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-4-431-53940-7"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674\u20107402.2023.01.015"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50574-6"},{"issue":"1","key":"e_1_2_10_9_1","first-page":"20","article-title":"Research progress of immune checkpoint inhibitors in the treatment of patients with metastatic colorectal cancer","volume":"12","author":"Chen H","year":"2020","journal-title":"J Digest Tumors"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9921-7"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"220","article-title":"Research advances in adverse liver reactions caused by immune checkpoint inhibitors","volume":"38","author":"Yu W","year":"2022","journal-title":"J Clin Hepatol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i22.2994"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14889"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100170"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801497105"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13141"},{"issue":"2","key":"e_1_2_10_19_1","first-page":"101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick SDH","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201602-095AW"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-0970-0"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-121808-102144"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glu057"},{"key":"e_1_2_10_24_1","first-page":"4","article-title":"Mycophenolate mofetil as a successful treatment of corticosteroid\u2010resistant immune checkpoint inhibitor\u2010induced hepatitis","volume":"4","author":"Kenji N","year":"2020","journal-title":"Oxf Med Case Rep"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omaa027"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15041"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.013"},{"issue":"2","key":"e_1_2_10_28_1","article-title":"Non\u2010transplant therapies for patients with hepatocellular carcinoma and child\u2010Pugh\u2010Turcotte class B cirrhosis","volume":"18","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T14:08:41Z","timestamp":1709129321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/cnr2.1918"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1918","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"2023-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1918"}}